Non-small cell lung cancer
Conditions
Interventions
Group A:to receive concomitant radiochemotherapy with pemetrexed + cisplatin: pemetrexed 500mg/m2, i.v. drip d1
cisplatin 25mg/m2, i.v. drip d1-3. Radiotherapy carried out in the 1st and 4th week.
Group B:to receive concomitant radiochemotherapy with vinorelbine and cisplatin: Vinorelbine 25mg/m2, i.v. drip d1, 8
Sponsors
Shandong Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Locally advanced lung cancer (III a, III b) which can not be surgically resected; 2. Measurable lesions with clear pathological diagnosis; 3. Life expectancy>=6 months; 4. Age: 18-75 years, male or female;5. General state of health: ECOG 0-1 grade; 6. Pulmonary function: FEV1>70%; 7. Without any chemotherapy or radiotherapy; 8. Signed informed consent; 9. Subjects meet the following criteria for the clinical laboratory: HG>=100g/L, WBC>=3.5*10^9/L, neutrophilic leukocyte>=1.5*10^9, PLT100*10^9/L, CR<=1.5 *N, TB<=2.5*N, AST and ALT<=2.5*N, AKP<=2.5*N.
Exclusion criteria
Exclusion criteria: 1. Serious infection; 2. Uncontrollable diabetes: blood glucose> 200mg% any time; patients with blood glucose> 200mg% while fasting blood glucose <140mg% may join group; 3. Other serious diseases, such as myocardial infarction in 6 months; 4. Participated other clinical trials in 4 weeks or at present.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| surviva; | — |
Secondary
| Measure | Time frame |
|---|---|
| effec; | — |
Countries
China
Contacts
Public ContactBaosheng Li
Outcome results
None listed